While there may have been a lot of attention on developing COVID vaccines, there has been less interest in investing in the vaccine safety monitoring mechanisms required under these extraordinary conditions. There is an urgency to get these systems in place both nationally and globally. An article in the New York Times explains how the much-touted system the government designed to monitor any dangerous reactions won’t be capable of analyzing safety data for weeks or months, according to numerous federal health officials.

Print Friendly, PDF & Email